X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ALKEM LABORATORIES - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ALKEM LABORATORIES DR. REDDYS LAB/
ALKEM LABORATORIES
 
P/E (TTM) x 22.6 - - View Chart
P/BV x 3.1 6.1 50.3% View Chart
Dividend Yield % 0.8 0.7 108.4%  

Financials

 DR. REDDYS LAB   ALKEM LABORATORIES
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
ALKEM LABORATORIES
Mar-16
DR. REDDYS LAB/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,8751,589 180.9%   
Low Rs1,8881,232 153.2%   
Sales per share (Unadj.) Rs930.2417.5 222.8%  
Earnings per share (Unadj.) Rs117.456.3 208.6%  
Cash flow per share (Unadj.) Rs185.864.7 287.1%  
Dividends per share (Unadj.) Rs20.0012.70 157.5%  
Dividend yield (eoy) %0.80.9 93.3%  
Book value per share (Unadj.) Rs844.4292.9 288.3%  
Shares outstanding (eoy) m166.07119.57 138.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.63.4 75.8%   
Avg P/E ratio x20.325.1 80.9%  
P/CF ratio (eoy) x12.821.8 58.8%  
Price / Book Value ratio x2.84.8 58.6%  
Dividend payout %17.022.6 75.5%   
Avg Mkt Cap Rs m395,496168,653 234.5%   
No. of employees `00022.0NA-   
Total wages/salary Rs m33,5629,171 365.9%   
Avg. sales/employee Rs Th7,032.8NM-  
Avg. wages/employee Rs Th1,527.9NM-  
Avg. net profit/employee Rs Th887.7NM-  
INCOME DATA
Net Sales Rs m154,48249,915 309.5%  
Other income Rs m3,3751,645 205.2%   
Total revenues Rs m157,85751,561 306.2%   
Gross profit Rs m31,7828,482 374.7%  
Depreciation Rs m11,3481,006 1,128.3%   
Interest Rs m889671 132.6%   
Profit before tax Rs m22,9208,451 271.2%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8581,606 240.2%   
Profit after tax Rs m19,5006,731 289.7%  
Gross profit margin %20.617.0 121.1%  
Effective tax rate %16.819.0 88.6%   
Net profit margin %12.613.5 93.6%  
BALANCE SHEET DATA
Current assets Rs m111,10127,062 410.5%   
Current liabilities Rs m58,97315,324 384.9%   
Net working cap to sales %33.723.5 143.5%  
Current ratio x1.91.8 106.7%  
Inventory Days Days7967 119.3%  
Debtors Days Days9441 228.2%  
Net fixed assets Rs m101,24512,610 802.9%   
Share capital Rs m830239 347.1%   
"Free" reserves Rs m139,40634,490 404.2%   
Net worth Rs m140,23635,027 400.4%   
Long term debt Rs m22,0001,212 1,815.8%   
Total assets Rs m224,65654,387 413.1%  
Interest coverage x26.813.6 196.9%   
Debt to equity ratio x0.20 453.5%  
Sales to assets ratio x0.70.9 74.9%   
Return on assets %9.113.6 66.7%  
Return on equity %13.919.2 72.4%  
Return on capital %14.924.9 60.1%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m88,6736,563 1,351.0%   
Fx outflow Rs m19,1043,012 634.3%   
Net fx Rs m69,5693,552 1,958.8%   
CASH FLOW
From Operations Rs m28,7047,259 395.5%  
From Investments Rs m-7,7271,864 -414.5%  
From Financial Activity Rs m-21,326-9,273 230.0%  
Net Cashflow Rs m-314-150 209.3%  

Share Holding

Indian Promoters % 25.5 66.9 38.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 33.1 16.3%  
FIIs % 35.3 0.0 -  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 0.0 -  
Shareholders   75,885 68,381 111.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   PROCTER & GAMBLE HEALTH  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jul 19, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS